Brainsway vs Neuronetics
BWAY and STIM side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BWAY and STIM compare
Brainsway grew revenue faster over the last twelve months (27.3% versus 23.0% for Neuronetics).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BWAY | STIM |
|---|---|---|
| Size and price | ||
| Market cap | – | $106M |
| Share price | $10.25 | $1.39 |
| Change, 1 year | 35.0% | −35.6% |
| Change, 5 years | 158% | −65.3% |
| Beta (5Y) | 1.27 | 1.59 |
| Employees | 129 | 658 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.7× |
| P/B | – | 5.7× |
| FCF yield | – | −9.1% |
| Growth | ||
| Revenue growth (TTM) | 27.3% (better) | 23.0% |
| Revenue growth, 5Y average | 18.8% | 24.8% (better) |
| EPS growth (TTM) | 260% | – |
| Profitability | ||
| Gross margin | 75.4% (better) | 50.7% |
| Operating margin | 8.3% (better) | −9.4% |
| Net margin | – | −14.4% |
| FCF margin | – | −6.0% |
| Return on equity | – | −100% |
| Return on invested capital | – | −19.2% |
| Financial health | ||
| Debt / equity | – | 3.30 |
| Interest coverage | 2.0× (better) | −1.7× |
| Current ratio | 3.59 (better) | 2.01 |
| Altman Z-score | – | −3.38 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 29.2% | 48.8% |
| Held by insiders | 25.5% | 51.3% |
| Insider net buying, 12 months | – | $4.6M |
| Short interest, % of float | – | 18.0% |
Go deeper
- BWAY stock overview
- BWAY income statement
- BWAY valuation and score
- STIM stock overview
- STIM income statement
- STIM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.